Effect of fenofibrate treatment on plasma lipoprotein lipids, high-density lipoprotein cholesterol subfractions, and apolipoproteins B, AI, AII, and E

The American Journal of Medicine

Volumn 83, Issue 5 SUPPL. 2, 1987, Pages 75-84

  Knopp, Robert H ^a   Walden, Carolyn E ^a   Warnick, G Russell ^a   Albers, John J ^a   Ginsberg, Janice ^a   McGinnis, Barbara M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; APOLIPOPROTEIN E; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN;

ADULT; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HYPERCHOLESTEROLEMIA; ORAL DRUG ADMINISTRATION;

ADULT; AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; APOLIPOPROTEINS; APOLIPOPROTEINS A; APOLIPOPROTEINS B; APOLIPOPROTEINS E; CLINICAL TRIALS; DOUBLE-BLIND METHOD; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPOPROTEINS; LIPOPROTEINS, HDL CHOLESTEROL; MALE; MIDDLE AGE; PROCETOFEN; PROPIONATES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023639089     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9343(87)90875-8     Document Type: Article

References (32)

1. Effects of fenofibrate on plasma lipids
2. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia
3. Effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia
4. Fenofibrate affects the compositions of lipoproteins
5. High-density lipoproteins during hypolipidemic therapy: a comparative study of four drugs
6. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia
7. Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease
8. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man
9. Variations in lipids and proteins of lipoproteins by fenofibrate in some hyperlipoproteinemic states
10. Fenofibrate: influence on circulating lipids and side-effects in medium and long-term clinical use
11. Arteriosclerosis risk and the roles of oral contraceptives and postmenopausal estrogens
12. Distribution of high density lipoprotein particles with different apoprotein composition: particles with A-I and A-II and particles with A-I but no A-II
13. Apoproteins B and A-I and coronary artery disease in humans
14. Lipoprotein receptors in the liver control signals for cholesterol traffic
15. Extrahepatic synthesis of apolipoprotein E
16. Expression of LDL receptor binding determinants in very low-density lipoproteins
17. Studies on the structure of low-density lipoprotein isolated from Macaca fascicularis fed an atherogenic diet
18. 2+ precipitation
19. Immunoassay of human plasma apolipoprotein B
20. Quantitation of apolipoprotein A-I of human plasma high-density lipoprotein
21. The measurement of apolipoprotein A-I and A-II levels in men and women by immunoassay
22. The effect of a high cholesterol and saturated fat diet on serum high-density lipoprotein cholesterol apoprotein A-I, and apoprotein E levels in normolipidemic humans
23. Relationship of gender, sex hormone use, and age on the lipoprotein cholesterol/triglyceride ratio in an adult population: The Pacific Northwest Bell Telephone Company health survey
24. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency
25. Prevalence and clinical correlates of beta-migrating VLDL: The Lipid Research Clinics Program Prevalence Study
26. Triglycerides and coronary heart disease mortality. The Lipid Research Clinics follow-up study
27. Studies of hypercholesterolemia in the nonhuman primate
28. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis: the Bogalusa Heart Study
29. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of the NHLBI Type II Coronary Intervention Study
30. 3 and A-apoproteins are dose-dependent